Anthrarobin

• CAT Number: I022230
• CAS Number: 577-33-3
• Molecular Formula: C14H10O3
• Molecular Weight: 226.23
• Purity: 98%
• Synonyms: Anthrarobin; NSC 60015; NSC-60015; NSC60015
• Target: Bacterial
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: anthracene-1,2,10-triol
• InChI: InChI=1S/C14H10O3/c15-12-6-5-10-11(14(12)17)7-8-3-1-2-4-9(8)13(10)16/h1-7,15-17H
• InChIKey: TZIQWQARHPGHIG-UHFFFAOYSA-N
• SMILES: Oc1c(cccc2)c2cc3c(O)c(O)ccc31

Anthrarobin is an antipsoriatic.

Reference

1: SCHALTEGGER H, KREBS A, KUSKE H. [ANALYSIS OF THE STRUCTURE OF ANTHRAROBIN AND ITS ACTION IN PSORIASIS]. Dermatologica. 1965;130:348-57. German. PubMed PMID: 14331066.
2: Kim YH, Moody JD, Freeman JP, Brezna B, Engesser KH, Cerniglia CE. Evidence for the existence of PAH-quinone reductase and catechol-O-methyltransferase in Mycobacterium vanbaalenii PYR-1. J Ind Microbiol Biotechnol. 2004 Dec;31(11):507-16. Epub 2004 Nov 11. PubMed PMID: 15549609.
3: HAXTHAUSEN H, SCHOU SA. [Anthrarobin and substitutes]. Ugeskr Laeger. 1950 May 4;112(18):631-2. Undetermined Language. PubMed PMID: 15424984.
4: Keller-Melchior R, Bräuninger W. Allergic contact dermatitis from anthrarobin. Contact Dermatitis. 1995 Nov;33(5):361. PubMed PMID: 8565505.
5: SIDI E, HINCKY M. [Comparative action of various reducing agents in the local treatment of psoriasis; clinical experimentation on anthrarobin]. Concours Med. 1956 May 19;78(20):2342-50. French. PubMed PMID: 13330357.
6: Sheu SY, Chiang HC. Inhibition of xanthine oxidase by hydroxylated anthraquinones and related compounds. Anticancer Res. 1997 Sep-Oct;17(5A):3293-7. PubMed PMID: 9413162.
7: Lateef M, Azhar A, Siddiqui BS, Zarina S, Uddin N, Anwar MF, Siddiqui K, Azhar KF, Iqbal L, Mehmood R, Perveen S. New anthrarobin acyl derivatives as butyrylcholinesterase inhibitors: synthesis, in vitro and in silico studies. Heliyon. 2017 Jul 10;3(7):e00350. doi: 10.1016/j.heliyon.2017.e00350. eCollection 2017 Jul. PubMed PMID: 28725871; PubMed Central PMCID: PMC5506883.
8: Krebs A, Schaltegger H Sr, Schaltegger A Jr. Structure specificity of the antipsoriatic anthrones. Br J Dermatol. 1981 Aug;105 Suppl 20:6-11. PubMed PMID: 7284267.
9: Hiipakka RA, Zhang HZ, Dai W, Dai Q, Liao S. Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol. 2002 Mar 15;63(6):1165-76. PubMed PMID: 11931850.
10: Ríos-Santamarina I, García-Domenech R, Gálvez J, Cortijo J, Santamaria P, Morcillo E. New bronchodilators selected by molecular topology. Bioorg Med Chem Lett. 1998 Mar 3;8(5):477-82. PubMed PMID: 9871602.
11: Churchill MR, Keil KM, Bright FV, Pandey S, Baker GA, Keister JB. Linkage and redox isomerism in ruthenium complexes of catecholate, semiquinone, and o-acylphenolate ligands derived from 1,2-dihydroxy-9,10-anthracenedione (alizarin) and related species: syntheses, characterizations, and photophysics. Inorg Chem. 2000 Dec 11;39(25):5807-16. PubMed PMID: 11151384.
12: Savić TD, Janković IA, Šaponjić ZV, Čomor MI, Veljković DŽ, Zarić SD, Nedeljković JM. Surface modification of anatase nanoparticles with fused ring catecholate type ligands: a combined DFT and experimental study of optical properties. Nanoscale. 2012 Mar 7;4(5):1612-9. doi: 10.1039/c2nr11501h. Epub 2012 Feb 6. PubMed PMID: 22310856.